25 XP   0   0   10

Sarepta Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Sarepta together

PenkeI guess you are interested in Sarepta Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sarepta Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sarepta Therapeutics Inc

I send you an email if I find something interesting about Sarepta Therapeutics Inc.

Quick analysis of Sarepta (30 sec.)










What can you expect buying and holding a share of Sarepta? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$8.14
Expected worth in 1 year
$12.17
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$4.04
Return On Investment
3.2%

For what price can you sell your share?

Current Price per Share
$127.39
Expected price per share
$89.92 - $143.00
How sure are you?
50%

1. Valuation of Sarepta (5 min.)




Live pricePrice per Share (EOD)

$127.39

Intrinsic Value Per Share

$-44.88 - $53.06

Total Value Per Share

$-36.74 - $61.20

2. Growth of Sarepta (5 min.)




Is Sarepta growing?

Current yearPrevious yearGrowGrow %
How rich?$859.3m$599.7m$169.6m22.1%

How much money is Sarepta making?

Current yearPrevious yearGrowGrow %
Making money-$133.9m-$175.8m$41.8m31.3%
Net Profit Margin-53.5%-75.8%--

How much money comes from the company's main activities?

3. Financial Health of Sarepta (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#64 / 1010

Most Revenue
#46 / 1010

Most Profit
#990 / 1010

Most Efficient
#533 / 1010

What can you expect buying and holding a share of Sarepta? (5 min.)

Welcome investor! Sarepta's management wants to use your money to grow the business. In return you get a share of Sarepta.

What can you expect buying and holding a share of Sarepta?

First you should know what it really means to hold a share of Sarepta. And how you can make/lose money.

Speculation

The Price per Share of Sarepta is $127.39. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sarepta.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sarepta, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $8.14. Based on the TTM, the Book Value Change Per Share is $1.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.45 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sarepta.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.430.3%-1.44-1.1%-1.87-1.5%-1.56-1.2%-1.06-0.8%
Usd Book Value Change Per Share-0.010.0%1.010.8%-1.45-1.1%-0.14-0.1%0.140.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.010.0%1.010.8%-1.45-1.1%-0.14-0.1%0.140.1%
Usd Price Per Share96.43-117.50-98.30-112.13-80.38-
Price to Earnings Ratio55.76--33.06--15.74--28.04--23.76-
Price-to-Total Gains Ratio-16,450.17--3,884.97--114.29--859.97--466.28-
Price to Book Ratio11.85-14.85-18.48-14.52-13.16-
Price-to-Total Gains Ratio-16,450.17--3,884.97--114.29--859.97--466.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share127.39
Number of shares7
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.01-0.14
Usd Total Gains Per Share1.01-0.14
Gains per Quarter (7 shares)7.06-1.00
Gains per Year (7 shares)28.26-4.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1028180-4-14
2057460-8-18
3085740-12-22
401131020-16-26
501411300-20-30
601701580-24-34
701981860-28-38
802262140-32-42
902542420-36-46
1002832700-40-50

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%2.038.00.05.0%7.0103.00.06.4%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%6.014.00.030.0%13.027.00.032.5%38.070.02.034.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%1.00.0109.00.9%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%6.014.00.030.0%13.027.00.032.5%38.070.02.034.5%

Fundamentals of Sarepta

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 19:03:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sarepta Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sarepta earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Sarepta to the Biotechnology industry mean.
  • A Net Profit Margin of 11.5% means that $0.12 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sarepta Therapeutics Inc:

  • The MRQ is 11.5%. The company is making a huge profit. +2
  • The TTM is -53.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ11.5%TTM-53.5%+65.0%
TTM-53.5%YOY-75.8%+22.3%
TTM-53.5%5Y-95.1%+41.6%
5Y-95.1%10Y-4,450.3%+4,355.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.5%-207.2%+218.7%
TTM-53.5%-216.8%+163.3%
YOY-75.8%-282.3%+206.5%
5Y-95.1%-436.8%+341.7%
10Y-4,450.3%-597.3%-3,853.0%
1.1.2. Return on Assets

Shows how efficient Sarepta is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sarepta to the Biotechnology industry mean.
  • 1.4% Return on Assets means that Sarepta generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sarepta Therapeutics Inc:

  • The MRQ is 1.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is -4.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.4%TTM-4.4%+5.8%
TTM-4.4%YOY-5.7%+1.3%
TTM-4.4%5Y-5.7%+1.3%
5Y-5.7%10Y-9.4%+3.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4%-13.3%+14.7%
TTM-4.4%-12.8%+8.4%
YOY-5.7%-11.6%+5.9%
5Y-5.7%-13.8%+8.1%
10Y-9.4%-15.6%+6.2%
1.1.3. Return on Equity

Shows how efficient Sarepta is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sarepta to the Biotechnology industry mean.
  • 5.3% Return on Equity means Sarepta generated $0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sarepta Therapeutics Inc:

  • The MRQ is 5.3%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -18.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ5.3%TTM-18.9%+24.3%
TTM-18.9%YOY-33.1%+14.1%
TTM-18.9%5Y-20.7%+1.8%
5Y-20.7%10Y-19.6%-1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3%-16.9%+22.2%
TTM-18.9%-16.1%-2.8%
YOY-33.1%-14.9%-18.2%
5Y-20.7%-19.3%-1.4%
10Y-19.6%-20.1%+0.5%

1.2. Operating Efficiency of Sarepta Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sarepta is operating .

  • Measures how much profit Sarepta makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sarepta to the Biotechnology industry mean.
  • An Operating Margin of 5.9% means the company generated $0.06  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sarepta Therapeutics Inc:

  • The MRQ is 5.9%. The company is operating less efficient.
  • The TTM is -22.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ5.9%TTM-22.7%+28.7%
TTM-22.7%YOY-57.5%+34.8%
TTM-22.7%5Y-75.9%+53.1%
5Y-75.9%10Y-4,624.4%+4,548.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.9%-298.0%+303.9%
TTM-22.7%-238.5%+215.8%
YOY-57.5%-288.4%+230.9%
5Y-75.9%-486.2%+410.3%
10Y-4,624.4%-628.4%-3,996.0%
1.2.2. Operating Ratio

Measures how efficient Sarepta is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.94 means that the operating costs are $0.94 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 0.938. The company is less efficient in keeping operating costs low.
  • The TTM is 1.264. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.938TTM1.264-0.326
TTM1.264YOY1.575-0.311
TTM1.2645Y1.781-0.517
5Y1.78110Y88.605-86.823
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9383.235-2.297
TTM1.2643.310-2.046
YOY1.5753.838-2.263
5Y1.7815.679-3.898
10Y88.6057.823+80.782

1.3. Liquidity of Sarepta Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sarepta is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.95 means the company has $3.95 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 3.946. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.744. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.946TTM4.744-0.798
TTM4.744YOY4.643+0.101
TTM4.7445Y6.045-1.301
5Y6.04510Y6.706-0.661
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9463.863+0.083
TTM4.7444.169+0.575
YOY4.6435.337-0.694
5Y6.0456.122-0.077
10Y6.7066.434+0.272
1.3.2. Quick Ratio

Measures if Sarepta is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sarepta to the Biotechnology industry mean.
  • A Quick Ratio of 5.15 means the company can pay off $5.15 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 5.146. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.159. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.146TTM6.159-1.013
TTM6.159YOY5.818+0.341
TTM6.1595Y6.641-0.482
5Y6.64110Y8.164-1.524
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1463.504+1.642
TTM6.1593.991+2.168
YOY5.8185.371+0.447
5Y6.6416.088+0.553
10Y8.1646.395+1.769

1.4. Solvency of Sarepta Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sarepta assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sarepta to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.74 means that Sarepta assets are financed with 73.7% credit (debt) and the remaining percentage (100% - 73.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 0.737. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.755. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.737TTM0.755-0.018
TTM0.755YOY0.804-0.049
TTM0.7555Y0.686+0.069
5Y0.68610Y0.475+0.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7370.339+0.398
TTM0.7550.337+0.418
YOY0.8040.271+0.533
5Y0.6860.368+0.318
10Y0.4750.388+0.087
1.4.2. Debt to Equity Ratio

Measures if Sarepta is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sarepta to the Biotechnology industry mean.
  • A Debt to Equity ratio of 279.9% means that company has $2.80 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sarepta Therapeutics Inc:

  • The MRQ is 2.799. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.094. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.799TTM3.094-0.295
TTM3.094YOY4.786-1.692
TTM3.0945Y2.940+0.154
5Y2.94010Y1.668+1.271
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7990.392+2.407
TTM3.0940.403+2.691
YOY4.7860.335+4.451
5Y2.9400.427+2.513
10Y1.6680.461+1.207

2. Market Valuation of Sarepta Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sarepta generates.

  • Above 15 is considered overpriced but always compare Sarepta to the Biotechnology industry mean.
  • A PE ratio of 55.76 means the investor is paying $55.76 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sarepta Therapeutics Inc:

  • The EOD is 73.659. Based on the earnings, the company is expensive. -2
  • The MRQ is 55.757. Based on the earnings, the company is expensive. -2
  • The TTM is -33.056. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD73.659MRQ55.757+17.902
MRQ55.757TTM-33.056+88.813
TTM-33.056YOY-15.737-17.319
TTM-33.0565Y-28.036-5.020
5Y-28.03610Y-23.758-4.277
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD73.659-2.300+75.959
MRQ55.757-2.656+58.413
TTM-33.056-2.718-30.338
YOY-15.737-4.145-11.592
5Y-28.036-6.258-21.778
10Y-23.758-6.315-17.443
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sarepta Therapeutics Inc:

  • The EOD is -45.632. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -34.542. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -21.692. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-45.632MRQ-34.542-11.090
MRQ-34.542TTM-21.692-12.850
TTM-21.692YOY-26.521+4.828
TTM-21.6925Y-22.620+0.928
5Y-22.62010Y-20.226-2.394
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-45.632-2.974-42.658
MRQ-34.542-3.306-31.236
TTM-21.692-3.508-18.184
YOY-26.521-5.613-20.908
5Y-22.620-8.378-14.242
10Y-20.226-8.873-11.353
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sarepta is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 11.85 means the investor is paying $11.85 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Sarepta Therapeutics Inc:

  • The EOD is 15.653. Based on the equity, the company is expensive. -2
  • The MRQ is 11.849. Based on the equity, the company is expensive. -2
  • The TTM is 14.845. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD15.653MRQ11.849+3.804
MRQ11.849TTM14.845-2.996
TTM14.845YOY18.479-3.634
TTM14.8455Y14.520+0.325
5Y14.52010Y13.162+1.358
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD15.6531.914+13.739
MRQ11.8492.116+9.733
TTM14.8452.097+12.748
YOY18.4792.881+15.598
5Y14.5203.550+10.970
10Y13.1623.936+9.226
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Sarepta Therapeutics Inc.

3.1. Institutions holding Sarepta Therapeutics Inc

Institutions are holding 87.992% of the shares of Sarepta Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc9.39330.018688161242431802.8366
2023-12-31BlackRock Inc6.61850.015362117921780572.951
2023-12-31HHG PLC5.69580.30755345785-436664-7.5515
2023-12-31Capital Research & Mgmt Co - Division 35.05190.102547414852917797159.9943
2023-12-31venBio Select Advisor LLC4.62895.786643444443194447.9365
2023-12-31Wellington Management Company LLP4.39780.074241276102178105.5709
2023-12-31State Street Corporation2.55610.0113239907841350220.8253
2023-12-31Bank of New York Mellon Corp2.48210.04552329556-181811-7.2395
2023-12-31T. Rowe Price Investment Management,Inc.2.04540.12041919742244221.2885
2023-12-31FMR Inc1.60570.01121507064-404189-21.1479
2023-12-31Deutsche Bank AG1.57150.0726147496240384437.703
2023-12-31Geode Capital Management, LLC1.56570.01481469537607624.3131
2023-12-31Morgan Stanley - Brokerage Accounts1.47050.0117138014952470561.3372
2023-12-31JPMorgan Chase & Co1.38780.01211302557-3305758-71.7346
2023-09-30Citadel Advisors Llc1.30840.0319122797433726137.8642
2023-12-31Bank of America Corp1.29170.01181212377684531129.6838
2023-12-31Farallon Capital Management, L.L.C.1.28930.57921210073-165127-12.0075
2023-12-31Pictet Asset Manangement SA1.16310.1161109160212665813.1259
2023-12-31Casdin Capital, LLC1.07249.52721006500-3830-0.3791
2023-12-31NORGES BANK0.89160.0141836849-26872-3.1112
Total 57.487516.884653955260+1927722+3.6%

3.2. Funds holding Sarepta Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.96870.0232786301-6534-0.234
2024-02-29Vanguard Small Cap Index2.44060.20852290672212250.9352
2023-12-31Vanguard Health Care Inv2.43320.4744228365600
2023-12-31Capital Group Growth Fnd of Amer Comp1.68390.0612158041843515037.9955
2023-12-31American Funds Growth Fund of Amer A1.68390.0612158041843515037.9955
2023-12-31VA CollegeAmerica Amcap 529A1.6430.185115420911120251265.563
2023-12-31Capital Group AMCAP Composite1.6430.185115420911120251265.563
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.47450.1735138387113000.094
2024-02-29Vanguard Small Cap Growth Index Inv1.36920.4711285057192811.5233
2023-12-31Janus Henderson Enterprise D1.10150.5063103384900
2023-12-31Janus Inst Mid Cap Growth CF1.10150.5072103384900
2023-12-31American Funds Fundamental Invs A1.06480.0771999416641481179.2172
2023-12-31Capital Group Fundamental Invtrs Comp1.06480.0771999416641481179.2172
2023-12-31Janus Henderson Global Life Sciences D0.97971.8017919473-1558-0.1692
2023-12-31Janus Henderson Global Life Sciences0.97971.8101919473-1558-0.1692
2023-12-31T. Rowe Price US Mid-Cap Growth Equity0.95670.285897900-2100-0.2333
2023-12-31T. Rowe Price Mid-Cap Growth0.95670.2859897900-2100-0.2333
2024-02-29DWS Vermögensbildungsfonds I LD0.8990.7772843800-2-0.0002
2023-12-31Janus Selection Global Life Science AUSD0.73981.8106694377-14138-1.9954
2024-03-28iShares Biotechnology ETF0.70611.1242662680-1154-0.1738
Total 27.890310.905426176708+4406426+16.8%

3.3. Insider Transactions

Insiders are holding 4.302% of the shares of Sarepta Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-11Kathryn Jean BoorSELL761122.93
2024-03-08Hans Lennart Rudolf WigzellSELL15000123.25
2024-03-05Stephen MayoSELL3135122.96
2024-03-01Bilal ArifSELL2000128.84
2024-03-01Ian Michael EstepanSELL1200128.3
2023-11-03Douglas S IngramBUY2522579.36
2023-11-03Richard BarryBUY5000078.81
2023-08-14Michael Andrew ChambersBUY9979109.47
2023-08-10Michael Andrew ChambersBUY34867106.15
2023-08-04Hans Lennart Rudolf WigzellSELL15000106.72

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Sarepta Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0061.009-101%-1.447+24577%-0.143+2340%0.138-104%
Book Value Per Share--8.1387.944+2%6.391+27%8.472-4%6.417+27%
Current Ratio--3.9464.744-17%4.643-15%6.045-35%6.706-41%
Debt To Asset Ratio--0.7370.755-2%0.804-8%0.686+7%0.475+55%
Debt To Equity Ratio--2.7993.094-10%4.786-42%2.940-5%1.668+68%
Dividend Per Share----0%-0%-0%-0%
Eps--0.432-1.441+433%-1.874+533%-1.562+461%-1.057+344%
Free Cash Flow Per Share---0.698-1.545+121%-0.949+36%-1.019+46%-0.847+21%
Free Cash Flow To Equity Per Share---0.680-1.213+78%-0.329-52%0.177-484%0.296-329%
Gross Profit Margin---3.785-0.196-95%1.000-479%0.761-598%0.882-529%
Intrinsic Value_10Y_max--53.064--------
Intrinsic Value_10Y_min---44.878--------
Intrinsic Value_1Y_max---2.131--------
Intrinsic Value_1Y_min---4.976--------
Intrinsic Value_3Y_max---0.727--------
Intrinsic Value_3Y_min---14.625--------
Intrinsic Value_5Y_max--7.521--------
Intrinsic Value_5Y_min---23.843--------
Market Cap11956239406.000+15%10182429420.00011310997799.500-10%9225985820.000+10%10580509806.500-4%7571973532.650+34%
Net Profit Margin--0.115-0.535+565%-0.758+759%-0.951+926%-44.503+38777%
Operating Margin--0.059-0.227+483%-0.575+1067%-0.759+1376%-46.244+77865%
Operating Ratio--0.9381.264-26%1.575-40%1.781-47%88.605-99%
Pb Ratio15.653+24%11.84914.845-20%18.479-36%14.520-18%13.162-10%
Pe Ratio73.659+24%55.757-33.056+159%-15.737+128%-28.036+150%-23.758+143%
Price Per Share127.390+24%96.430117.500-18%98.300-2%112.129-14%80.376+20%
Price To Free Cash Flow Ratio-45.632-32%-34.542-21.692-37%-26.521-23%-22.620-35%-20.226-41%
Price To Total Gains Ratio-21731.699-32%-16450.175-3884.971-76%-114.286-99%-859.974-95%-466.280-97%
Quick Ratio--5.1466.159-16%5.818-12%6.641-23%8.164-37%
Return On Assets--0.014-0.044+414%-0.057+508%-0.057+509%-0.094+774%
Return On Equity--0.053-0.189+457%-0.331+723%-0.207+490%-0.196+470%
Total Gains Per Share---0.0061.009-101%-1.447+24577%-0.143+2340%0.138-104%
Usd Book Value--859337000.000769463500.000+12%599783250.000+43%799884950.000+7%604677775.000+42%
Usd Book Value Change Per Share---0.0061.009-101%-1.447+24577%-0.143+2340%0.138-104%
Usd Book Value Per Share--8.1387.944+2%6.391+27%8.472-4%6.417+27%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.432-1.441+433%-1.874+533%-1.562+461%-1.057+344%
Usd Free Cash Flow---73696000.000-147084500.000+100%-89042500.000+21%-96004100.000+30%-79716150.000+8%
Usd Free Cash Flow Per Share---0.698-1.545+121%-0.949+36%-1.019+46%-0.847+21%
Usd Free Cash Flow To Equity Per Share---0.680-1.213+78%-0.329-52%0.177-484%0.296-329%
Usd Market Cap11956239406.000+15%10182429420.00011310997799.500-10%9225985820.000+10%10580509806.500-4%7571973532.650+34%
Usd Price Per Share127.390+24%96.430117.500-18%98.300-2%112.129-14%80.376+20%
Usd Profit--45655000.000-133994250.000+393%-175872000.000+485%-146372400.000+421%-99078450.000+317%
Usd Revenue--396781000.000310834000.000+28%233253250.000+70%189958400.000+109%106780425.000+272%
Usd Total Gains Per Share---0.0061.009-101%-1.447+24577%-0.143+2340%0.138-104%
 EOD+4 -4MRQTTM+22 -12YOY+26 -85Y+21 -1310Y+20 -14

4.2. Fundamental Score

Let's check the fundamental score of Sarepta Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1573.659
Price to Book Ratio (EOD)Between0-115.653
Net Profit Margin (MRQ)Greater than00.115
Operating Margin (MRQ)Greater than00.059
Quick Ratio (MRQ)Greater than15.146
Current Ratio (MRQ)Greater than13.946
Debt to Asset Ratio (MRQ)Less than10.737
Debt to Equity Ratio (MRQ)Less than12.799
Return on Equity (MRQ)Greater than0.150.053
Return on Assets (MRQ)Greater than0.050.014
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Sarepta Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.709
Ma 20Greater thanMa 50123.102
Ma 50Greater thanMa 100125.927
Ma 100Greater thanMa 200116.329
OpenGreater thanClose123.000
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -1,6641,245-419-636-1,055417-6381,556918
Income before Tax  -101,306-411,404-512,710498,125-14,585-18,589-33,17473,54540,371
Net Income  -109,244-407,511-516,755492,815-23,940-16,997-40,93786,59245,655
Depreciation and Amortization  25,3434,99230,335-19,54310,79213610,928-62,983-52,055
Operating Income  -106,833-31,255-138,0884,569-133,519112,677-20,84245,46724,625
Tax Provision  7,938-3,8934,0455,3109,355-1,5927,763-13,047-5,284
Income Tax Expense  7,938-3,8934,0455,3109,355-1,5927,763-13,047-5,284
Net Income from Continuing Operations  -109,244-399,421-508,665484,725-23,940-16,997-40,93786,59245,655



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets3,264,576
Total Liabilities2,405,239
Total Stockholder Equity859,337
 As reported
Total Liabilities 2,405,239
Total Stockholder Equity+ 859,337
Total Assets = 3,264,576

Assets

Total Assets3,264,576
Total Current Assets2,579,331
Long-term Assets685,245
Total Current Assets
Cash And Cash Equivalents 428,430
Short-term Investments 1,247,820
Net Receivables 439,706
Inventory 322,859
Other Current Assets 140,516
Total Current Assets  (as reported)2,579,331
Total Current Assets  (calculated)2,579,331
+/-0
Long-term Assets
Property Plant Equipment 357,106
Long Term Investments 6,527
Intangible Assets 29,620
Long-term Assets Other 276,413
Long-term Assets  (as reported)685,245
Long-term Assets  (calculated)669,666
+/- 15,579

Liabilities & Shareholders' Equity

Total Current Liabilities653,659
Long-term Liabilities1,751,580
Total Stockholder Equity859,337
Total Current Liabilities
Short-term Debt 123,328
Short Long Term Debt 105,483
Accounts payable 164,918
Other Current Liabilities 314,997
Total Current Liabilities  (as reported)653,659
Total Current Liabilities  (calculated)708,726
+/- 55,067
Long-term Liabilities
Long term Debt 1,132,515
Capital Lease Obligations 158,810
Long-term Liabilities Other 41,100
Long-term Liabilities  (as reported)1,751,580
Long-term Liabilities  (calculated)1,332,425
+/- 419,155
Total Stockholder Equity
Common Stock9
Retained Earnings -4,446,213
Accumulated Other Comprehensive Income 918
Other Stockholders Equity 5,304,623
Total Stockholder Equity (as reported)859,337
Total Stockholder Equity (calculated)859,337
+/-0
Other
Capital Stock9
Cash and Short Term Investments 1,676,250
Common Stock Shares Outstanding 105,594
Current Deferred Revenue50,416
Liabilities and Stockholders Equity 3,264,576
Net Debt 968,378
Net Invested Capital 2,097,335
Net Working Capital 1,925,672
Property Plant and Equipment Gross 548,076
Short Long Term Debt Total 1,396,808



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-31
> Total Assets 
0
0
0
4,200
3,700
18,500
19,400
18,800
17,500
15,800
12,600
10,200
8,000
5,700
3,800
12,900
15,791
12,427
40,015
35,088
30,456
39,373
33,140
33,815
33,815
37,532
30,743
28,604
21,333
39,624
37,115
47,145
45,802
38,142
32,373
28,519
45,698
40,543
39,516
56,408
58,119
52,384
46,542
40,863
35,307
31,209
26,865
38,638
35,480
32,578
29,515
25,536
37,017
32,617
65,123
60,027
52,825
48,667
50,860
45,976
47,031
74,933
61,083
54,368
46,647
42,101
53,082
204,993
193,340
183,633
304,479
291,569
275,389
337,309
319,058
295,033
242,708
231,710
184,751
273,782
213,364
204,068
487,310
424,104
511,533
450,139
800,281
1,307,964
1,300,283
1,247,160
1,182,906
1,642,075
1,963,895
1,747,753
1,702,470
1,822,822
2,947,388
2,883,043
2,780,664
2,984,718
2,765,233
2,759,073
2,662,218
3,147,974
3,056,154
2,996,853
3,156,149
3,128,366
3,059,786
3,125,890
3,109,707
3,264,576
3,264,5763,109,7073,125,8903,059,7863,128,3663,156,1492,996,8533,056,1543,147,9742,662,2182,759,0732,765,2332,984,7182,780,6642,883,0432,947,3881,822,8221,702,4701,747,7531,963,8951,642,0751,182,9061,247,1601,300,2831,307,964800,281450,139511,533424,104487,310204,068213,364273,782184,751231,710242,708295,033319,058337,309275,389291,569304,479183,633193,340204,99353,08242,10146,64754,36861,08374,93347,03145,97650,86048,66752,82560,02765,12332,61737,01725,53629,51532,57835,48038,63826,86531,20935,30740,86346,54252,38458,11956,40839,51640,54345,69828,51932,37338,14245,80247,14537,11539,62421,33328,60430,74337,53233,81533,81533,14039,37330,45635,08840,01512,42715,79112,9003,8005,7008,00010,20012,60015,80017,50018,80019,40018,5003,7004,200000
   > Total Current Assets 
0
0
0
3,100
2,300
17,600
18,500
17,700
16,300
14,500
11,500
9,000
6,700
4,400
2,500
11,700
14,429
10,597
38,269
33,131
27,478
35,860
28,818
27,511
27,511
30,266
23,029
20,402
12,581
30,778
28,314
38,391
37,157
29,648
23,804
20,198
37,475
32,431
31,500
48,653
50,767
45,101
39,289
33,940
28,307
21,215
16,754
28,711
25,363
22,546
19,660
17,044
28,779
24,329
56,947
51,310
44,149
39,932
42,314
37,838
38,495
66,023
51,945
45,184
37,632
33,232
42,159
193,908
176,594
172,906
290,422
270,806
249,370
304,671
269,815
247,796
193,049
182,394
122,108
224,543
160,726
153,194
434,744
373,476
457,307
390,585
735,608
1,228,644
1,219,417
1,139,244
1,012,077
1,426,183
1,671,423
1,427,418
1,362,299
1,468,913
2,547,348
2,459,421
2,322,673
2,485,196
2,271,350
2,265,217
2,185,310
2,604,099
2,530,947
2,469,300
2,625,929
2,557,861
2,488,377
2,472,614
2,450,849
2,579,331
2,579,3312,450,8492,472,6142,488,3772,557,8612,625,9292,469,3002,530,9472,604,0992,185,3102,265,2172,271,3502,485,1962,322,6732,459,4212,547,3481,468,9131,362,2991,427,4181,671,4231,426,1831,012,0771,139,2441,219,4171,228,644735,608390,585457,307373,476434,744153,194160,726224,543122,108182,394193,049247,796269,815304,671249,370270,806290,422172,906176,594193,90842,15933,23237,63245,18451,94566,02338,49537,83842,31439,93244,14951,31056,94724,32928,77917,04419,66022,54625,36328,71116,75421,21528,30733,94039,28945,10150,76748,65331,50032,43137,47520,19823,80429,64837,15738,39128,31430,77812,58120,40223,02930,26627,51127,51128,81835,86027,47833,13138,26910,59714,42911,7002,5004,4006,7009,00011,50014,50016,30017,70018,50017,6002,3003,100000
       Cash And Cash Equivalents 
0
0
0
3,000
2,300
17,600
18,500
17,600
15,800
13,200
10,900
8,500
6,700
4,400
2,400
8,700
9,580
6,949
29,555
25,899
22,002
28,132
24,613
11,069
11,069
13,445
12,589
10,385
7,172
9,078
6,530
12,525
8,687
11,045
12,342
16,655
34,357
27,346
27,557
34,598
36,867
31,764
25,578
20,159
14,965
9,264
3,861
24,803
19,961
18,509
14,081
11,192
24,723
20,037
50,268
48,275
41,438
36,742
35,967
33,589
23,283
54,188
46,356
39,904
30,573
24,491
37,987
187,661
167,919
156,185
273,644
256,965
49,101
102,754
52,299
73,551
74,436
69,538
55,819
80,304
38,001
111,819
395,140
122,420
274,723
168,348
617,630
599,691
557,234
410,375
209,702
370,829
732,190
808,591
724,829
835,080
1,764,212
1,639,959
1,474,637
1,502,648
1,481,836
1,697,275
1,599,113
2,115,869
1,233,877
868,565
1,038,624
966,777
871,668
851,929
541,932
428,430
428,430541,932851,929871,668966,7771,038,624868,5651,233,8772,115,8691,599,1131,697,2751,481,8361,502,6481,474,6371,639,9591,764,212835,080724,829808,591732,190370,829209,702410,375557,234599,691617,630168,348274,723122,420395,140111,81938,00180,30455,81969,53874,43673,55152,299102,75449,101256,965273,644156,185167,919187,66137,98724,49130,57339,90446,35654,18823,28333,58935,96736,74241,43848,27550,26820,03724,72311,19214,08118,50919,96124,8033,8619,26414,96520,15925,57831,76436,86734,59827,55727,34634,35716,65512,34211,0458,68712,5256,5309,0787,17210,38512,58913,44511,06911,06924,61328,13222,00225,89929,5556,9499,5808,7002,4004,4006,7008,50010,90013,20015,80017,60018,50017,6002,3003,000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,900
4,800
3,625
8,593
6,214
4,618
6,596
3,157
14,528
14,528
16,235
9,878
8,909
4,541
21,262
21,129
25,074
27,722
18,129
10,763
2,860
2,835
4,840
3,401
12,453
12,579
12,709
12,847
12,993
12,081
10,057
10,188
272
274
277
280
282
285
168
169
171
172
0
0
0
0
0
0
0
0
0
0
0
0
7,250
7,250
7,250
176,091
176,785
183,718
136,793
91,787
87,349
44,090
112,187
91,155
11,396
784
195,425
115,590
132,598
784
479,369
491,757
538,769
583,158
803,083
612,018
294,478
324,063
289,668
406,940
421,349
341,467
435,923
255,997
30,000
0
0
779,548
1,059,454
1,033,860
1,022,597
1,010,429
1,008,786
1,191,610
1,247,820
1,247,8201,191,6101,008,7861,010,4291,022,5971,033,8601,059,454779,5480030,000255,997435,923341,467421,349406,940289,668324,063294,478612,018803,083583,158538,769491,757479,369784132,598115,590195,42578411,39691,155112,18744,09087,34991,787136,793183,718176,785176,0917,2507,2507,25000000000000017217116916828528228027727427210,18810,05712,08112,99312,84712,70912,57912,4533,4014,8402,8352,86010,76318,12927,72225,07421,12921,2624,5418,9099,87816,23514,52814,5283,1576,5964,6186,2148,5933,6254,8002,900000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,715
1,715
501
507
513
519
437
0
0
0
0
0
0
0
0
0
1,236
840
44
61
51
552
1,120
1,751
2,870
4,053
2,666
4,077
4,971
3,126
3,360
5,671
2,085
1,648
2,153
5,241
3,224
13,576
10,892
4,267
3,633
5,135
7,180
2,474
4,713
5,652
3,788
6,721
3,530
7,849
5,226
3,362
2,416
2,416
2,416
2,733
3,977
3,990
3,982
3,986
5,228
12,278
17,791
24,751
29,468
39,848
53,394
48,601
49,044
107,569
94,480
71,091
93,938
109,934
107,087
124,886
138,583
136,367
148,264
181,558
171,637
197,201
230,275
223,450
259,697
288,076
267,158
354,263
439,706
439,706354,263267,158288,076259,697223,450230,275197,201171,637181,558148,264136,367138,583124,886107,087109,93493,93871,09194,480107,56949,04448,60153,39439,84829,46824,75117,79112,2785,2283,9863,9823,9903,9772,7332,4162,4162,4163,3625,2267,8493,5306,7213,7885,6524,7132,4747,1805,1353,6334,26710,89213,5763,2245,2412,1531,6482,0855,6713,3603,1264,9714,0772,6664,0532,8701,7511,1205525161448401,2360000000004375195135075011,7151,71500000000000000000000000
       Other Current Assets 
0
0
0
100
0
0
0
100
500
1,300
600
500
0
0
100
100
49
23
122
1,019
858
1,131
1,049
199
199
85
55
595
349
437
655
791
748
474
699
683
283
245
543
366
481
584
803
736
709
775
953
767
1,075
1,094
1,223
599
645
764
839
779
891
1,037
1,106
1,025
15,212
11,835
5,589
1,647
1,924
1,561
4,172
1,534
3,023
5,683
2,807
3,061
9,079
15,906
26,436
1,571
443
455
634
1,201
1,071
1,105
1,556
914
956
1,140
1,022
36,511
2,400
1,868
54,800
77,782
4,949
5,927
5,109
5,249
5,867
3,222
3,231
4,065
5,369
4,905
5,678
6,142
7,008
9,805
11,059
7,722
9,878
11,459
13,669
140,516
140,51613,66911,4599,8787,72211,0599,8057,0086,1425,6784,9055,3694,0653,2313,2225,8675,2495,1095,9274,94977,78254,8001,8682,40036,5111,0221,1409569141,5561,1051,0711,2016344554431,57126,43615,9069,0793,0612,8075,6833,0231,5344,1721,5611,9241,6475,58911,83515,2121,0251,1061,0378917798397646455991,2231,0941,07576795377570973680358448136654324528368369947474879165543734959555851991991,0491,1318581,0191222349100100005006001,300500100000100000
   > Long-term Assets 
0
0
0
1,100
1,400
900
900
1,100
1,200
1,300
1,100
1,200
1,300
1,300
1,300
1,200
1,362
1,829
1,746
1,957
2,978
3,513
4,322
0
6,304
7,266
7,714
8,202
8,751
8,847
8,801
8,755
8,645
8,494
8,570
8,320
8,224
8,112
8,017
7,755
7,352
7,283
7,253
6,923
7,000
9,993
10,111
9,926
10,117
10,032
9,855
8,491
8,238
8,288
8,176
8,717
8,676
8,735
8,546
8,138
8,536
8,910
9,138
9,184
9,015
8,869
10,923
11,085
16,746
10,727
14,057
20,763
26,019
32,638
49,243
47,237
49,659
49,316
62,643
49,239
52,638
50,874
52,566
50,628
54,226
59,554
64,673
79,320
80,866
107,916
170,829
215,892
292,472
320,335
340,171
353,909
400,040
423,622
457,991
499,522
493,883
493,856
476,908
543,875
525,207
527,553
530,220
570,505
571,409
653,276
658,858
685,245
685,245658,858653,276571,409570,505530,220527,553525,207543,875476,908493,856493,883499,522457,991423,622400,040353,909340,171320,335292,472215,892170,829107,91680,86679,32064,67359,55454,22650,62852,56650,87452,63849,23962,64349,31649,65947,23749,24332,63826,01920,76314,05710,72716,74611,08510,9238,8699,0159,1849,1388,9108,5368,1388,5468,7358,6768,7178,1768,2888,2388,4919,85510,03210,1179,92610,1119,9937,0006,9237,2537,2837,3527,7558,0178,1128,2248,3208,5708,4948,6458,7558,8018,8478,7518,2027,7147,2666,30404,3223,5132,9781,9571,7461,8291,3621,2001,3001,3001,3001,2001,1001,3001,2001,1009009001,4001,100000
       Property Plant Equipment 
0
0
0
500
500
400
400
400
400
400
400
400
500
500
400
400
423
552
812
1,037
1,993
2,424
3,177
4,898
4,898
5,668
6,052
6,584
7,066
7,102
7,006
7,008
6,772
6,565
6,588
6,314
6,144
6,008
5,888
5,599
5,154
4,936
4,746
4,330
4,103
7,190
7,099
6,825
6,677
6,474
6,278
5,189
4,934
4,758
2,102
2,466
4,733
4,556
4,134
4,035
4,076
4,328
4,301
4,265
4,105
3,898
3,661
3,397
3,088
3,359
8,244
15,049
20,130
20,163
37,178
38,501
37,759
37,196
37,379
37,344
36,982
36,158
35,620
37,801
38,412
39,393
38,872
43,156
53,927
57,624
76,841
97,024
147,378
156,650
159,025
167,553
200,422
227,537
242,800
282,191
268,175
276,198
271,912
236,687
233,230
230,291
224,039
244,991
244,878
323,602
345,821
357,106
357,106345,821323,602244,878244,991224,039230,291233,230236,687271,912276,198268,175282,191242,800227,537200,422167,553159,025156,650147,37897,02476,84157,62453,92743,15638,87239,39338,41237,80135,62036,15836,98237,34437,37937,19637,75938,50137,17820,16320,13015,0498,2443,3593,0883,3973,6613,8984,1054,2654,3014,3284,0764,0354,1344,5564,7332,4662,1024,7584,9345,1896,2786,4746,6776,8257,0997,1904,1034,3304,7464,9365,1545,5995,8886,0086,1446,3146,5886,5656,7727,0087,0067,1027,0666,5846,0525,6684,8984,8983,1772,4241,9931,037812552423400400500500400400400400400400400500500000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,809
0
0
30,000
107,294
32,359
32,154
31,834
31,937
33,697
33,344
32,769
38,799
40,640
39,971
35,288
34,892
33,394
33,234
33,244
31,321
31,000
31,000
13,448
6,527
6,52713,44831,00031,00031,32133,24433,23433,39434,89235,28839,97140,64038,79932,76933,34433,69731,93731,83432,15432,359107,29430,0000021,809000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
500
500
600
600
600
600
600
700
700
700
800
800
800
850
895
904
891
955
1,059
1,115
1,376
1,376
1,568
1,632
1,588
1,656
1,715
1,765
1,716
1,842
1,894
1,947
1,969
2,042
2,067
2,091
2,118
2,163
2,312
2,472
2,559
2,611
2,769
2,977
3,067
3,404
3,523
3,543
3,268
3,269
3,452
3,580
3,759
3,832
4,068
4,301
3,980
4,074
4,459
4,698
4,764
4,704
4,740
4,837
4,913
4,883
5,186
5,231
5,042
5,217
5,387
5,689
5,891
5,842
6,024
6,116
6,642
6,728
6,991
8,111
8,076
7,684
7,795
14,029
14,355
14,473
14,857
15,324
11,574
11,781
11,825
11,975
12,497
12,813
13,105
13,344
13,628
14,124
14,105
14,204
14,239
13,328
13,062
13,057
7,578
7,199
18,018
19,501
29,620
29,62019,50118,0187,1997,57813,05713,06213,32814,23914,20414,10514,12413,62813,34413,10512,81312,49711,97511,82511,78111,57415,32414,85714,47314,35514,0297,7957,6848,0768,1116,9916,7286,6426,1166,0245,8425,8915,6895,3875,2175,0425,2315,1864,8834,9134,8374,7404,7044,7644,6984,4594,0743,9804,3014,0683,8323,7593,5803,4523,2693,2683,5433,5233,4043,0672,9772,7692,6112,5592,4722,3122,1632,1182,0912,0672,0421,9691,9471,8941,8421,7161,7651,7151,6561,5881,6321,5681,3761,3761,1151,059955891904895850800800800700700700600600600600600500500000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
939
1,278
934
920
985
1,089
1,145
1,406
1,510
1,598
1,662
1,618
1,686
1,744
1,795
1,746
1,872
1,929
1,981
2,007
2,080
2,105
2,129
2,156
2,198
2,347
2,507
2,593
2,897
2,804
3,012
3,102
3,440
3,558
3,577
3,303
3,304
3,530
6,074
6,251
6,315
6,551
6,391
6,068
6,425
6,547
6,693
4,919
4,910
4,971
7,262
7,688
13,658
7,368
5,813
5,714
5,889
12,475
12,065
8,736
11,900
12,120
25,264
11,895
15,656
14,716
16,946
12,827
15,814
20,161
25,801
36,164
12,466
35,435
48,664
75,555
133,313
119,706
137,337
141,922
153,108
149,636
169,078
295,464
211,584
163,582
155,504
292,949
245,255
250,966
259,880
286,615
288,332
280,656
0
0
00280,656288,332286,615259,880250,966245,255292,949155,504163,582211,584295,464169,078149,636153,108141,922137,337119,706133,31375,55548,66435,43512,46636,16425,80120,16115,81412,82716,94614,71615,65611,89525,26412,12011,9008,73612,06512,4755,8895,7145,8137,36813,6587,6887,2624,9714,9104,9196,6936,5476,4256,0686,3916,5516,3156,2516,0743,5303,3043,3033,5773,5583,4403,1023,0122,8042,8972,5932,5072,3472,1982,1562,1292,1052,0802,0071,9811,9291,8721,7461,7951,7441,6861,6181,6621,5981,5101,4061,1451,0899859209341,2789390000000000000000
> Total Liabilities 
0
0
0
300
3,500
900
800
500
500
400
1,200
1,200
700
400
700
1,000
767
1,105
1,316
1,723
1,618
1,614
1,582
3,281
3,281
3,955
4,916
5,122
1,620
1,296
2,309
3,751
2,750
2,167
1,349
2,250
2,278
1,927
2,523
2,748
2,210
2,265
2,183
3,151
4,347
6,994
11,639
12,256
14,694
11,335
13,176
9,804
14,127
28,829
45,619
36,397
29,352
40,226
46,697
48,793
46,111
39,784
29,331
23,351
32,625
19,601
57,648
81,314
106,059
94,812
57,495
44,377
46,427
37,388
32,854
47,380
41,949
66,334
61,515
83,435
74,402
82,609
78,686
87,413
82,391
72,367
103,125
518,747
523,523
548,113
543,058
609,799
615,331
648,586
707,266
1,004,635
1,802,560
1,840,177
1,888,617
2,222,959
2,229,788
2,273,965
2,192,690
2,219,965
2,199,268
2,270,396
2,725,309
2,743,416
2,347,037
2,384,479
2,345,350
2,405,239
2,405,2392,345,3502,384,4792,347,0372,743,4162,725,3092,270,3962,199,2682,219,9652,192,6902,273,9652,229,7882,222,9591,888,6171,840,1771,802,5601,004,635707,266648,586615,331609,799543,058548,113523,523518,747103,12572,36782,39187,41378,68682,60974,40283,43561,51566,33441,94947,38032,85437,38846,42744,37757,49594,812106,05981,31457,64819,60132,62523,35129,33139,78446,11148,79346,69740,22629,35236,39745,61928,82914,1279,80413,17611,33514,69412,25611,6396,9944,3473,1512,1832,2652,2102,7482,5231,9272,2782,2501,3492,1672,7503,7512,3091,2961,6205,1224,9163,9553,2813,2811,5821,6141,6181,7231,3161,1057671,0007004007001,2001,2004005005008009003,500300000
   > Total Current Liabilities 
0
0
0
300
400
900
800
500
500
400
1,200
1,200
700
400
800
1,000
767
1,105
1,316
1,723
1,618
1,614
1,582
3,281
3,281
3,955
4,916
5,122
1,620
1,296
2,309
3,751
2,750
2,167
1,349
2,250
2,278
1,927
2,523
2,748
2,210
2,265
2,183
3,151
4,347
4,887
9,550
9,752
12,142
8,827
10,666
7,288
11,616
26,288
43,059
33,507
26,341
37,268
43,765
45,857
43,220
36,938
26,531
20,601
29,923
17,131
55,200
78,886
103,659
92,433
51,101
35,966
37,758
29,404
22,726
36,867
33,906
38,962
37,667
62,294
55,160
66,930
64,933
75,422
74,629
65,960
70,470
88,332
91,196
104,687
114,393
173,690
137,366
162,089
215,856
264,767
306,429
354,896
378,388
416,026
364,736
425,022
373,443
452,733
454,962
545,566
602,916
619,604
536,884
498,654
450,743
653,659
653,659450,743498,654536,884619,604602,916545,566454,962452,733373,443425,022364,736416,026378,388354,896306,429264,767215,856162,089137,366173,690114,393104,68791,19688,33270,47065,96074,62975,42264,93366,93055,16062,29437,66738,96233,90636,86722,72629,40437,75835,96651,10192,433103,65978,88655,20017,13129,92320,60126,53136,93843,22045,85743,76537,26826,34133,50743,05926,28811,6167,28810,6668,82712,1429,7529,5504,8874,3473,1512,1832,2652,2102,7482,5231,9272,2782,2501,3492,1672,7503,7512,3091,2961,6205,1224,9163,9553,2813,2811,5821,6141,6181,7231,3161,1057671,0008004007001,2001,200400500500800900400300000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-881
0
0
0
0
0
0
69
70
71
26
73
74
74
75
76
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
90
91
92
94
96
2,512
2,590
4,930
5,008
5,889
8,429
7,604
10,106
10,107
10,108
11,346
11,217
4,732
6,175
3,446
9,514
88,687
134,095
100,120
107,328
121,663
0
176,298
159,088
199,063
80,367
180,636
240,141
221,009
271,697
0
0
0
15,489
0
326,877
322,350
123,328
123,328322,350326,877015,489000271,697221,009240,141180,63680,367199,063159,088176,2980121,663107,328100,120134,09588,6879,5143,4466,1754,73211,21711,34610,10810,10710,1067,6048,4295,8895,0084,9302,5902,5129694929190908988878685848382818079787776767574747326717069000000-88100000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,590
0
0
0
8,429
0
0
0
10,108
11,346
11,217
4,732
6,175
3,446
9,514
0
0
6,762
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
105,483
105,4830000000000000000006,762009,5143,4466,1754,73211,21711,34610,1080008,4290002,590000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
200
200
500
500
200
300
400
900
900
500
200
400
700
510
839
1,014
1,291
1,218
1,245
1,150
2,772
2,772
3,553
4,470
4,541
1,129
811
1,819
3,053
1,781
1,608
737
1,456
1,574
1,256
1,641
1,862
1,251
1,288
1,156
1,402
1,890
2,349
5,274
3,026
3,368
2,325
3,258
2,014
1,279
1,506
4,303
1,381
1,761
2,369
4,945
1,311
6,484
10,975
7,899
9,396
8,195
8,813
4,334
7,532
7,073
6,727
8,129
17,634
7,721
1,309
967
12,408
9,318
14,095
7,431
20,234
18,673
17,133
20,684
29,690
27,446
10,921
5,317
8,467
17,379
17,382
20,408
33,829
26,499
44,045
81,946
68,094
26,595
91,660
74,528
111,090
76,651
76,681
44,163
76,741
54,007
56,207
118,461
95,875
106,710
109,796
87,948
164,918
164,91887,948109,796106,71095,875118,46156,20754,00776,74144,16376,68176,651111,09074,52891,66026,59568,09481,94644,04526,49933,82920,40817,38217,3798,4675,31710,92127,44629,69020,68417,13318,67320,2347,43114,0959,31812,4089671,3097,72117,6348,1296,7277,0737,5324,3348,8138,1959,3967,89910,9756,4841,3114,9452,3691,7611,3814,3031,5061,2792,0143,2582,3253,3683,0265,2742,3491,8901,4021,1561,2881,2511,8621,6411,2561,5741,4567371,6081,7813,0531,8198111,1294,5414,4703,5532,7722,7721,1501,2451,2181,2911,014839510700400200500900900400300200500500200200000
       Other Current Liabilities 
0
0
0
100
200
400
300
300
200
0
300
300
200
200
400
300
257
265
302
432
400
369
432
509
509
402
446
581
491
485
490
698
969
559
612
793
704
670
881
886
959
977
1,027
1,749
2,457
1,337
2,880
5,918
7,152
4,154
5,090
3,010
8,103
22,578
36,584
28,621
21,093
31,454
35,405
41,161
33,350
22,576
15,244
7,816
18,338
4,927
47,474
67,961
92,612
81,117
38,918
14,941
26,640
24,696
15,885
18,551
16,295
16,556
21,044
30,328
25,580
36,388
30,839
32,321
32,534
40,519
57,118
70,374
4,723
74,488
1,995
2,463
6,762
7,413
8,944
196,673
12,463
14,837
15,553
135,325
18,205
18,956
19,027
15,051
311,711
400,115
395,211
418,996
362,935
16,992
17,951
314,997
314,99717,95116,992362,935418,996395,211400,115311,71115,05119,02718,95618,205135,32515,55314,83712,463196,6738,9447,4136,7622,4631,99574,4884,72370,37457,11840,51932,53432,32130,83936,38825,58030,32821,04416,55616,29518,55115,88524,69626,64014,94138,91881,11792,61267,96147,4744,92718,3387,81615,24422,57633,35041,16135,40531,45421,09328,62136,58422,5788,1033,0105,0904,1547,1525,9182,8801,3372,4571,7491,0279779598868816707047936125599696984904854915814464025095094323694004323022652573004002002003003000200300300400200100000
   > Long-term Liabilities 
0
0
0
0
3,100
0
0
0
0
0
0
0
0
0
-100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,107
2,089
2,504
2,552
2,508
2,510
2,516
2,511
2,541
2,560
2,890
3,011
2,958
2,932
2,936
2,891
2,846
2,800
2,750
2,702
2,470
2,448
2,428
2,400
2,379
6,394
8,411
8,669
7,984
10,128
10,513
8,043
27,372
23,848
21,141
19,242
15,678
13,753
11,991
7,762
6,407
32,655
430,415
432,327
443,426
428,665
436,109
477,965
486,497
491,410
739,868
1,496,131
1,485,281
1,510,229
1,806,933
1,865,052
1,848,943
1,819,247
1,767,232
1,744,306
1,724,830
2,122,393
2,123,812
1,810,153
1,885,825
1,894,607
1,751,580
1,751,5801,894,6071,885,8251,810,1532,123,8122,122,3931,724,8301,744,3061,767,2321,819,2471,848,9431,865,0521,806,9331,510,2291,485,2811,496,131739,868491,410486,497477,965436,109428,665443,426432,327430,41532,6556,4077,76211,99113,75315,67819,24221,14123,84827,3728,04310,51310,1287,9848,6698,4116,3942,3792,4002,4282,4482,4702,7022,7502,8002,8462,8912,9362,9322,9583,0112,8902,5602,5412,5112,5162,5102,5082,5522,5042,0892,107000000000000000000000000000000-1000000000003,1000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,800
1,778
1,757
1,735
1,713
1,690
1,668
1,645
1,622
1,599
1,576
1,551
1,525
3,763
3,738
1,450
20,652
17,397
14,969
13,373
10,111
8,491
6,042
2,343
0
26,550
424,876
427,365
429,925
415,446
420,554
425,752
431,040
436,421
681,900
687,953
694,156
700,470
992,493
1,091,110
1,092,985
1,094,912
1,096,876
1,098,847
1,100,873
1,542,770
0
1,234,284
0
0
0
0001,234,28401,542,7701,100,8731,098,8471,096,8761,094,9121,092,9851,091,110992,493700,470694,156687,953681,900436,421431,040425,752420,554415,446429,925427,365424,87626,55002,3436,0428,49110,11113,37314,96917,39720,6521,4503,7383,7631,5251,5511,5761,5991,6221,6451,6681,6901,7131,7351,7571,7781,8000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
433
454
474
495
515
530
579
610
966
1,108
1,075
1,069
1,094
1,070
1,046
1,022
993
967
757
758
760
755
757
4,795
6,835
7,118
6,459
6,365
6,775
6,593
6,720
6,451
6,172
5,869
5,567
5,262
5,949
5,419
6,407
6,105
5,539
4,962
13,501
13,219
15,555
48
5,248
5,248
10,248
742,915
718,724
741,530
734,073
713,267
690,673
660,907
628,844
606,839
584,589
544,394
521,942
521,938
0
0
0
000521,938521,942544,394584,589606,839628,844660,907690,673713,267734,073741,530718,724742,91510,2485,2485,2484815,55513,21913,5014,9625,5396,1056,4075,4195,9495,2625,5675,8696,1726,4516,7206,5936,7756,3656,4597,1186,8354,7957577557607587579679931,0221,0461,0701,0941,0691,0751,10896661057953051549547445443300000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,365
6,775
6,593
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000006,5936,7756,36500000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
3,900
200
17,600
18,600
18,300
17,000
15,400
11,400
9,000
7,300
5,300
3,100
11,900
15,024
11,322
38,698
33,366
28,838
37,758
31,559
30,534
30,534
33,576
25,827
23,482
19,713
38,328
34,806
43,394
43,051
35,975
31,024
26,269
43,420
38,616
36,994
53,660
55,909
50,119
44,359
37,712
30,960
24,215
15,226
26,382
20,786
21,243
16,339
15,732
22,890
3,788
19,504
23,630
23,473
8,441
4,163
-2,817
920
35,149
31,752
31,017
14,022
22,500
-4,566
123,679
87,281
88,821
246,984
247,192
228,962
299,921
286,204
247,653
200,759
165,376
123,236
190,347
138,962
121,459
408,624
336,691
429,142
377,772
697,156
789,217
776,760
699,047
639,848
1,032,276
1,348,564
1,099,167
995,204
818,187
1,144,828
1,042,866
892,047
761,759
535,445
485,108
469,528
928,009
856,886
726,457
430,840
384,950
712,749
741,411
764,357
859,337
859,337764,357741,411712,749384,950430,840726,457856,886928,009469,528485,108535,445761,759892,0471,042,8661,144,828818,187995,2041,099,1671,348,5641,032,276639,848699,047776,760789,217697,156377,772429,142336,691408,624121,459138,962190,347123,236165,376200,759247,653286,204299,921228,962247,192246,98488,82187,281123,679-4,56622,50014,02231,01731,75235,149920-2,8174,1638,44123,47323,63019,5043,78822,89015,73216,33921,24320,78626,38215,22624,21530,96037,71244,35950,11955,90953,66036,99438,61643,42026,26931,02435,97543,05143,39434,80638,32819,71323,48225,82733,57630,53430,53431,55937,75828,83833,36638,69811,32215,02411,9003,1005,3007,3009,00011,40015,40017,00018,30018,60017,6002003,900000
   Common Stock
0
0
0
3,100
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
6
7
7
7
7
9
9
11
11
11
11
11
11
11
14
13
13
13
2
2
3
3
3
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
6
6
6
7
7
7
7
7
7
7
8
8
8
8
8
8
8
8
9
9
9
9
9
9
9
9
9
999999999888888887777777666555555444444444333221313131411111111111111997777655555555444444433333332222222220000000000003,100000
   Retained Earnings Total Equity000-4,426,9910-3,800,992-3,543,254-3,311,773-3,206,748-3,084,767-3,036,623-2,955,218-2,848,129-2,658,812-2,462,313-2,311,493-2,294,001-2,058,298-1,931,972-1,655,569-1,578,926-1,438,031-1,361,638-1,252,371-1,217,008-1,193,010-1,145,276-1,082,230-1,166,320-1,077,868-1,021,126-958,825-899,055-834,374-782,435-740,584-679,025-634,609-605,383-571,509-543,236-534,416-492,386-473,335-431,251-369,184-319,630-327,668-309,964-308,554-304,5340000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-2,000
-2,100
-2,200
-2,300
-2,300
-2,300
-2,400
-2,400
-2,400
-2,500
-2,500
-2,500
1,903
728
-9,304
-11,683
-13,279
-11,301
-2,217
-2,941
1,039
415
-265
730
354
1,491
2,454
-290
-419
-425
-295
-133
-7,163
-7,595
-8,029
13
15
17
19
18
16
-11,034
-11,472
-11,817
-12,112
-11,817
-12,631
-12,919
-13,207
-13,492
-13,735
-14,026
-14,138
-14,393
-14,678
-14,963
-15,150
-15,338
-15,542
-15,765
-15,982
-16,208
-16,444
-16,708
-17,024
-17,173
-17,345
-17,328
-59
-35
-55
-95
-17
-19
-1
-111
-5
1
-28,426
-120
-55
-38
-12
-379
-643
-361
8
-99
19
82
75
50
624
6
-6
3
-3
2
-20
-20
-306
-2,485
-3,205
-1,664
-419
-1,055
-638
918
918-638-1,055-419-1,664-3,205-2,485-306-20-202-33-6662450758219-998-361-643-379-12-38-55-120-28,4261-5-111-1-19-17-95-55-35-59-17,328-17,345-17,173-17,024-16,708-16,444-16,208-15,982-15,765-15,542-15,338-15,150-14,963-14,678-14,393-14,138-14,026-13,735-13,492-13,207-12,919-12,631-11,817-12,112-11,817-11,472-11,034161819171513-8,029-7,595-7,163-133-295-425-419-2902,4541,491354730-2654151,039-2,941-2,217-11,301-13,279-11,683-9,3047281,903-2,500-2,500-2,500-2,400-2,400-2,400-2,300-2,300-2,300-2,200-2,100-2,0000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
339,669
340,293
340,968
341,677
342,128
364,616
554,927
560,613
581,204
781,396
790,424
800,526
905,335
920,864
926,769
941,356
947,826
957,607
1,089,508
1,097,787
1,142,580
1,486,487
1,503,126
1,511,422
1,523,080
1,890,172
2,006,598
2,029,767
2,061,039
2,077,864
2,611,294
3,004,107
3,031,050
3,053,420
3,112,130
3,455,689
3,505,165
3,550,857
3,609,877
3,490,658
3,521,721
3,554,307
4,134,768
4,168,956
4,272,187
4,235,028
0
5,140,150
0
0
0
0005,140,15004,235,0284,272,1874,168,9564,134,7683,554,3073,521,7213,490,6583,609,8773,550,8573,505,1653,455,6893,112,1303,053,4203,031,0503,004,1072,611,2942,077,8642,061,0392,029,7672,006,5981,890,1721,523,0801,511,4221,503,1261,486,4871,142,5801,097,7871,089,508957,607947,826941,356926,769920,864905,335800,526790,424781,396581,204560,613554,927364,616342,128341,677340,968340,293339,6690000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000-190,347000-247,653000-247,192000-123,6790000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
13,200
15,200
34,000
36,000
36,600
36,800
36,800
54,200
54,200
54,200
54,300
54,300
65,500
69,769
68,944
98,620
96,316
95,029
107,553
117,018
0
120,692
142,555
142,146
144,064
144,010
166,425
167,802
179,784
187,358
187,835
188,415
188,967
212,051
212,612
213,116
234,700
246,010
247,994
249,474
251,603
255,003
257,225
248,923
264,549
274,263
276,175
278,132
278,954
287,325
288,176
312,222
313,114
313,653
315,532
318,832
319,781
321,872
355,007
355,835
356,733
357,659
358,336
381,060
571,635
577,637
598,377
798,741
807,752
817,570
923,245
939,674
946,570
962,376
970,000
980,974
1,113,991
1,123,608
1,169,729
1,514,913
1,533,352
1,542,855
1,556,089
1,924,837
2,024,241
2,030,124
2,082,802
2,103,096
2,639,344
3,038,229
3,069,530
3,098,196
3,163,175
3,455,313
3,505,171
3,550,857
3,609,877
3,490,658
3,521,721
3,554,307
4,134,768
4,168,956
4,272,187
4,235,028
4,296,841
5,140,150
5,193,388
5,256,854
5,304,623
5,304,6235,256,8545,193,3885,140,1504,296,8414,235,0284,272,1874,168,9564,134,7683,554,3073,521,7213,490,6583,609,8773,550,8573,505,1713,455,3133,163,1753,098,1963,069,5303,038,2292,639,3442,103,0962,082,8022,030,1242,024,2411,924,8371,556,0891,542,8551,533,3521,514,9131,169,7291,123,6081,113,991980,974970,000962,376946,570939,674923,245817,570807,752798,741598,377577,637571,635381,060358,336357,659356,733355,835355,007321,872319,781318,832315,532313,653313,114312,222288,176287,325278,954278,132276,175274,263264,549248,923257,225255,003251,603249,474247,994246,010234,700213,116212,612212,051188,967188,415187,835187,358179,784167,802166,425144,010144,064142,146142,555120,6920117,018107,55395,02996,31698,62068,94469,76965,50054,30054,30054,20054,20054,20036,80036,80036,60036,00034,00015,20013,200000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,243,336
Cost of Revenue-150,343
Gross Profit1,092,9931,092,993
 
Operating Income (+$)
Gross Profit1,092,993
Operating Expense-1,360,817
Operating Income-267,824-267,824
 
Operating Expense (+$)
Research Development877,387
Selling General Administrative481,871
Selling And Marketing Expenses0
Operating Expense1,360,8171,359,258
 
Net Interest Income (+$)
Interest Income67,659
Interest Expense-22,010
Other Finance Cost-1,454
Net Interest Income44,195
 
Pretax Income (+$)
Operating Income-267,824
Net Interest Income44,195
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-520,098-15,550
EBIT - interestExpense = -348,726
-520,098
-513,967
Interest Expense22,010
Earnings Before Interest and Taxes (EBIT)-326,716-498,088
Earnings Before Interest and Taxes (EBITDA)-267,824
 
After tax Income (+$)
Income Before Tax-520,098
Tax Provision-29,101
Net Income From Continuing Ops-690,876-549,199
Net Income-535,977
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,511,160
Total Other Income/Expenses Net-252,274-44,195
 

Technical Analysis of Sarepta
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sarepta. The general trend of Sarepta is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sarepta's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sarepta Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 131.16 < 142.60 < 143.00.

The bearish price targets are: 99.49 > 91.34 > 89.92.

Tweet this
Sarepta Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sarepta Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sarepta Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sarepta Therapeutics Inc. The current macd is -1.26849219.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sarepta price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Sarepta. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Sarepta price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Sarepta Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartSarepta Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sarepta Therapeutics Inc. The current adx is 22.33.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sarepta shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Sarepta Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sarepta Therapeutics Inc. The current sar is 114.59.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Sarepta Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sarepta Therapeutics Inc. The current rsi is 59.71. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Sarepta Therapeutics Inc Daily Relative Strength Index (RSI) ChartSarepta Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sarepta Therapeutics Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sarepta price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Sarepta Therapeutics Inc Daily Stochastic Oscillator ChartSarepta Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sarepta Therapeutics Inc. The current cci is 59.09.

Sarepta Therapeutics Inc Daily Commodity Channel Index (CCI) ChartSarepta Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sarepta Therapeutics Inc. The current cmo is 33.95.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Sarepta Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartSarepta Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sarepta Therapeutics Inc. The current willr is -19.82758621.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Sarepta Therapeutics Inc Daily Williams %R ChartSarepta Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sarepta Therapeutics Inc. The current atr is 4.08133803.

Sarepta Therapeutics Inc Daily Average True Range (ATR) ChartSarepta Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sarepta Therapeutics Inc. The current obv is 13,641,877.

Sarepta Therapeutics Inc Daily On-Balance Volume (OBV) ChartSarepta Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sarepta Therapeutics Inc. The current mfi is 47.68.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Sarepta Therapeutics Inc Daily Money Flow Index (MFI) ChartSarepta Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sarepta Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Sarepta Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sarepta Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.709
Ma 20Greater thanMa 50123.102
Ma 50Greater thanMa 100125.927
Ma 100Greater thanMa 200116.329
OpenGreater thanClose123.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sarepta with someone you think should read this too:
  • Are you bullish or bearish on Sarepta? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sarepta? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sarepta Therapeutics Inc

I send you an email if I find something interesting about Sarepta Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Sarepta Therapeutics Inc.

Receive notifications about Sarepta Therapeutics Inc in your mailbox!